# A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

> **NCT04466891** · PHASE2 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 87 (actual)

## Conditions studied

- HER2-amplified Biliary Tract Cancers

## Interventions

- **DRUG:** ZW25 (Zanidatamab)

## Key facts

- **NCT ID:** NCT04466891
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-01
- **Primary completion:** 2023-07-28
- **Final completion:** 2024-07-11
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2025-09-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04466891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04466891, "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04466891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*